Skip to main content

Branded

  • FDA approves Teva’s Vantrela ER

    SILVER SPRING, Md. — The Food and Drug Administration has approved Teva’s Vantrela ER (hydrocodone bitartrate, extended-release) tablets, the company announced Wednesday. The drug, indicated for pain severe enough to require daily, around-the-clock, long-term opioid treatment and patients for whom alternative therapy is inadequate, is formulated with Teva’s proprietary abuse-deterrent technology. 
     

  • Lilly to acquire CoLucid Pharmaceuticals

    INDIANAPOLIS and CAMBRIDGE, Mass. — Eli Lilly on Wednesday announced its planned acquisition of CoLucid Pharmaceuticals. The $960 million all-cash transaction is aimed at growing Lilly’s migraine pain management portfolio and will add a potential near-term launch to its late-stage pipeline. 
     

  • Bayer taps Brunn to lead pharmaceuticals business in Americas region

    WHIPPANY, N.J. — Bayer on Tuesday announced that it had named Carsten Brunn as president of its pharmaceuticals division in the Americas. Brunn will oversee the company’s pharmaceutical arm in the United States, Canada, Central and Latin America, reporting to pharmaceutical division president and board of management member Dieter Weinand. 
     

  • Walgreens Flu Index captures budding flu season by market

    DEERFIELD, Ill.  — The latest Walgreens Flu Index issued Thursday recorded sharp upticks in several U.S. markets, including those markets in Utah, Mississippi, Hawaii and Puerto Rico.

  • Mayne Pharma launches Fabior, Sorilux

    GREENVILLE, N.C. — Mayne Pharma on Wednesday announced the launch of Fabior (tazarotene, 0.1%) Foam and Sorilux (calcipotiene, 0.005%) Foam. Mayne Pharma acquired the products from GSK in August 2016, and they complement the company’s Doryx, the first branded product in its specialty brands division that it launched in 2015. 
     

  • AstraZeneca announces Bevespi Aerosphere’s U.S. availability

    WILMINGTON, Del. — AstraZeneca on Monday announced the availability of its Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol in the United States. The drug is indicated for long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis or emphysema. 
     

  • FDA approves Egalet’s abuse-deterrent morphine Arymo ER

    SILVER SPRING, Md. — The Food and Drug Administration has approved Arymo ER (morphine sulfate), an extended-release morphine tablet with abuse-deterrent properties, the company announced Monday. 
     

  • PhRMA names Duato new board chairman

    WASHINGTON — The Pharmaceutical Research and Manufacturers of America have announced Monday that Joaquin Duato, Johnson & Johnson’s worldwide chairman, pharmaceuticals, would be succeeding George Scangos, the outgoing CEO of Biogen, as the organization’s board chairman. 
     
X
This ad will auto-close in 10 seconds